In breast cancer patients, HER2+ subtypes of breast cancer accounts for 20–30%, which is an invasive tumor with shorter metastatic time and poor prognosis compared to other two subtypes of breast cancer patients [2]. Here, ERBB2 is linked to breast carcinoma.